Representative before the EPO

Technology company logo thumb
no operation time available
3 offices
Technology Company

Andrew George Smith has worked on the following 44 EPO patent applications which have been published in the last five years:

EP12723323

NOVEL IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF ARTHRITIS

IPC classification:
A61K 31/4439, A61P 19/02, C07D 403/04, C07D 403/12
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12727984

PYRAZOLE DERIVATIVES USEFUL AS ALDOSTERONE SYNTHASE INHIBITORS

IPC classification:
A61K 31/416, A61P 5/00, A61P 9/00, A61P 13/00, C07D 231/54, C07D 231/56
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12735409

(THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS

IPC classification:
A61K 31/55, A61P 25/00, C07D 498/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
GRANT OF PATENT INTENDED
EP12748334

NOVEL 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVE USEFUL FOR THE TREATMENT OF DIABETES

IPC classification:
A61K 31/381, A61K 31/4709, C07D 409/06
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12756856

(THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS

IPC classification:
A61K 31/5513, A61P 25/04, C07D 498/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP12775406

SELECTIVE ANDROGEN RECEPTOR MODULATORS

IPC classification:
A61K 31/136, A61K 31/341, A61K 31/351, A61P 21/00, C07C 255/58, C07D 307/22, C07D 309/14
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP12783804

COMBINATION THERAPY FOR OVARIAN CANCER

IPC classification:
A61K 31/437, A61K 31/555, A61K 31/7068, A61P 35/00
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP12795315

SPIROTHIENOPYRAN- PIPERIDINE DERIVATIVES AS ORL-1 RECEPTOR ANTAGONISTS FOR THEIR USE IN THE TREATMENT OF ALCOHOL DEPENDENCE AND ABUSE

IPC classification:
A61K 31/435, A61P 25/32
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP12701824

SUBSTITUTED [(5H-PYRROLO[2,1-c] [1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS

IPC classification:
A61K 31/5517, A61P 25/20, C07D 487/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13701550

PHENYL METHANESULFONAMIDE DERIVATIVES USEFUL AS MGAT - 2 INHIBITORS

IPC classification:
A61K 31/445, A61P 3/06, C07D 211/42, C07D 211/44, C07D 213/06, C07D 213/24, C07D 277/64, C07D 295/03, C07D 401/04, C07D 417/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13703234

BENZYL SULFONAMIDE DERIVATIVES USEFUL AS MOGAT - 2 INHIBITORS

IPC classification:
A61K 31/4402, A61P 3/10, C07C 311/05, C07D 213/64, C07D 213/65
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP13702564

NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS

IPC classification:
A61K 31/5375, A61P 3/00, C07D 265/30, C07D 295/03, C07D 295/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12741192

NOTCH PATHWAY SIGNALING INHIBITOR COMPOUND

IPC classification:
A61K 38/05, A61P 35/00, A61P 35/02, C07D 401/04, C07D 471/04, C07K 5/062
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11776639

CATHEPSIN S INHIBITOR COMPOUNDS

IPC classification:
A61K 31/496, A61P 9/00, C07D 407/04, C07D 407/14
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP11808065

NOVEL IMIDAZOLE-2-BENZAMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF OSTEOARTHRITIS

IPC classification:
A61K 31/4168, A61P 29/00, C07D 233/88
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13722231

PYRAZOLE COMPOUNDS AS SGLT1 INHIBITORS

IPC classification:
A61K 31/4155, A61K 31/438, A61P 3/10, C07D 471/10, C07D 487/10
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13729215

INHIBITOR OF JAK1 AND JAK2

IPC classification:
A61K 31/4155, A61P 35/00, C07D 471/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP13734248

PHENOXYETHYL PIPERIDINE COMPOUNDS

IPC classification:
A61K 31/45, A61P 19/00, A61P 29/00, C07D 211/60
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
GRANT OF PATENT INTENDED
EP13789443

NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS

IPC classification:
C07D 207/00, C07D 217/00, C07D 263/00, C07D 273/00, C07D 307/00, C07D 309/00, C07D 311/00, C07D 319/00
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
GRANT OF PATENT INTENDED
EP11713150

PURINE COMPOUNDS USED AS CB2 AGONISTS

IPC classification:
A61K 31/52, A61P 25/06, A61P 29/00, C07D 473/34
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14701636

(THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS

IPC classification:
A61K 31/55, A61P 25/00, C07D 498/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP12701207

IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUND AND ITS USE AS PI3 KINASE / MTOR DUAL INHIBITOR

IPC classification:
A61K 31/4745, A61P 35/00, C07D 471/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14712966

CDC7 Inhibitors

IPC classification:
C07D 403/14
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP11788263

COMPOUNDS USEFUL FOR INHIBITING CHK1

IPC classification:
A61K 31/4995, A61P 35/00, C07D 401/14
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14727692

PHENOXYETHYL DIHYDRO-1H-ISOQUINOLINE COMPOUNDS

IPC classification:
A61K 31/472, A61P 29/00, C07D 217/26
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP14732756

3,4-DIHYDROISOQUINOLIN-2(1H)-YL COMPOUNDS

IPC classification:
A61K 31/472, A61P 25/16, A61P 25/18, C07D 217/16
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
GRANT OF PATENT INTENDED
EP11741372

6-(1-METHYL-1H-PYRAZOL-4-YL)-3-(2-METHYL-2H-INDAZOL-5-YLTHIO)-[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE AS A C-MET INHIBITOR

IPC classification:
A61K 31/501, A61P 35/00, C07D 487/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14796332

1 -(BETA-D-GLUCOPYRANOSYL)-1H-INDOLE COMPOUNDS

IPC classification:
A61K 31/438, A61P 3/10, C07D 487/10
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP14793753

GLUCOPYRANOSYL-SUBSTITUTED INDOLE-UREA DERIVATIVES AND THEIR USE AS SGLT INHIBITORS

IPC classification:
A61K 31/7042, C07H 19/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP14802974

4-{4-[(1 E)-4-(2,9-DIAZASPIRO[5.5]UNDEC-2-YL)BUT-1 -EN-1 -YL]-2-METHYLBENZYL}-5-(PROPAN-2-YL)-1 H-PYRAZOL-3-YL BETA-D- GLUCOPYRANOSIDE ACETATE

IPC classification:
A61K 31/7056, A61P 3/10, C07H 17/02
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP14800188

PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS

IPC classification:
A61K 31/519, A61P 35/00, C07D 471/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
The patent has been granted
EP14802755

SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN O-ACYL TRANSFERASE INHIBITOR

IPC classification:
A61K 31/506, A61P 3/00, C07D 401/06
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
The patent has been granted
EP11713138

PURINE COMPOUNDS

IPC classification:
A61K 31/52, A61P 25/02, C07D 487/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14809734

NOVEL DGAT2 INHIBITORS

IPC classification:
A61K 31/506, A61P 3/00, A61P 9/00, C07D 239/42
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP14816539

A NOVEL TRIAZOLO-PYRIDINE COMPOUND

IPC classification:
A61K 31/4196, A61P 5/00, C07D 249/18
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP14827907

PHENOXYETHYL CYCLIC AMINE DERIVATIVES AND THEIR ACTIVITY AS EP4 RECEPTOR MODULATORS

IPC classification:
A61K 31/438, A61K 31/445, A61K 31/45, A61P 19/02, C07D 207/16, C07D 209/52, C07D 211/60, C07D 217/26, C07D 221/04, C07D 221/20
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP14827909

FLUOROPHENYL PYRAZOL COMPOUNDS

IPC classification:
A61K 31/45, A61P 3/04, C07D 231/20, C07D 401/12, C07D 403/12
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP14827908

DIMETHYLBENZOIC ACID COMPOUNDS

IPC classification:
C07C 215/52, C07C 233/81, C07C 235/42, C07D 213/81, C07D 401/12, C07D 405/02
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15700618

ISOPROPYL TRIAZOLO PYRIDINE COMPOUNDS

IPC classification:
A61K 31/437, A61P 3/10, C07D 471/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15702019

PHENYL-TRIAZOLO-PYRIDINE COMPOUNDS

IPC classification:
A61K 31/437, A61P 3/00, C07D 471/04
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15749214

GPR142 AGONIST COMPOUNDS

IPC classification:
A61K 31/4164, A61K 31/4178, A61P 3/10, C07D 233/58, C07D 233/60, C07D 233/61
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15708638

COMBINATION THERAPY FOR CANCER

IPC classification:
A61K 31/506, A61K 39/395, A61P 35/00
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15767383

TREATMENT OF ANDROGEN DEPRIVATION THERAPY ASSOCIATED SYMPTOMS

IPC classification:
A61K 31/4439, A61P 5/26, A61P 19/08, A61P 21/00, A61P 21/06
Applicant:
Eli Lilly and Company Limited
Agent:
Andrew George Smith, Eli Lilly and Company Limited
Status:
Request for examination was made

Please Sign in to use this feature